{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:10:12Z","timestamp":1787026212743,"version":"build-2736575974"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"abstract":"<jats:p>Seasonal influenza viruses account for 1 billion infections worldwide every year, including 3\u20135 million cases of severe illness and up to 650,000 deaths. The effectiveness of current influenza virus vaccines is variable and relies on the immunodominant hemagglutinin (HA) and to a lesser extent on the neuraminidase (NA), the viral surface glycoproteins. Efficient vaccines that refocus the immune response to conserved epitopes on the HA are needed to tackle infections by influenza virus variants. Sequential vaccination with chimeric HA (cHA) and mosaic HA (mHA) constructs has proven to induce immune responses to the HA stalk domain and conserved epitopes on the HA head. In this study, we developed a bioprocess to manufacture cHA and mHA inactivated split vaccines and a method to quantify HA with a prefusion stalk based on a sandwich enzyme-linked immunosorbent assay. Virus inactivation with beta-propiolactone (\u03b2PL) and splitting with Triton X-100 yielded the highest amount of prefusion HA and enzymatically active NA. In addition, the quantity of residual Triton X-100 and ovalbumin (OVA) was reduced to very low levels in the final vaccine preparations. The bioprocess shown here provides the basis to manufacture inactivated split cHA and mHA vaccines for pre-clinical research and future clinical trials in humans, and can also be applied to produce vaccines based on other influenza viruses.<\/jats:p>","DOI":"10.3389\/fbioe.2023.1097349","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T01:23:13Z","timestamp":1685928193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses"],"prefix":"10.3389","volume":"11","author":[{"given":"Eduard","family":"Puente-Massaguer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Beyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhumathi","family":"Loganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iden","family":"Sapse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goran","family":"Bajic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/22221751.2018.1564369","article-title":"Cross-reactive antibodies binding to H4 hemagglutinin protect against a lethal H4N6 influenza virus challenge in the mouse model","volume":"8","author":"Amanat","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"B2","first-page":"1696","article-title":"Broadly cross-reactive, nonneutralizing antibodies against influenza B virus hemagglutinin demonstrate effector function-dependent protection against lethal viral challenge in mice","volume-title":"Journal of virology","author":"Asthagiri Arunkumar","year":"2019"},{"key":"B3","doi-asserted-by":"publisher","first-page":"S405","DOI":"10.1093\/infdis\/jiab269","article-title":"Influenza vaccines: Successes and continuing challenges","volume":"224","author":"Becker","year":"2021","journal-title":"J. Infect. Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/s1473-3099(19)30393-7","article-title":"Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: Interim results of a randomised, placebo-controlled, phase 1 clinical trial","volume":"20","author":"Bernstein","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.ymthe.2022.01.011","article-title":"A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice","volume":"30","author":"Bliss","year":"2022","journal-title":"Mol. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bbamem.2013.09.021","article-title":"Treatment of influenza virus with beta-propiolactone alters viral membrane fusion","volume":"1838","author":"Bonnafous","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e30898","DOI":"10.1371\/journal.pone.0030898","article-title":"Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: The role of viral membrane fusion activity","volume":"7","author":"Budimir","year":"2012","journal-title":"PLoS One"},{"key":"B8","first-page":"1343","article-title":"Highly conserved protective epitopes on influenza B viruses","volume-title":"Science","author":"Dreyfus","year":"2012"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.00286-17","article-title":"Chimeric hemagglutinin constructs induce broad protection against influenza B virus challenge in the mouse model","volume":"91","author":"Ermler","year":"2017","journal-title":"J. Virol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/s1473-3099(22)00024-x","article-title":"Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: A phase 1-2 randomised controlled trial","volume":"22","author":"Folschweiller","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6703a1","article-title":"Prevention and control of seasonal influenza with vaccines: Recommendations of the advisory committee on immunization practices-United States, 2018-19 influenza season","volume":"67","author":"Grohskopf","year":"2018","journal-title":"MMWR Recomm. Rep."},{"key":"B12","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/mop.0b013e32834ac7a3","article-title":"An update on influenza vaccination in patients with egg allergy","volume":"23","author":"Gruenberg","year":"2011","journal-title":"Curr. Opin. Pediatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1128\/jvi.00137-12","article-title":"Influenza viruses expressing chimeric hemagglutinins: Globular head and stalk domains derived from different subtypes","volume":"86","author":"Hai","year":"2012","journal-title":"J. Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"10580","DOI":"10.1128\/jvi.01213-08","article-title":"Influenza B virus NS1-truncated mutants: Live-attenuated vaccine approach","volume":"82","author":"Hai","year":"2008","journal-title":"J. Virol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"20248","DOI":"10.1073\/pnas.1320524110","article-title":"Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins","volume":"110","author":"Heaton","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1016\/j.jaip.2021.04.020","article-title":"The hidden allergen: Triton X-100, a derivative of polyethylene glycol","volume":"9","author":"Herman","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/j.vaccine.2019.01.086","article-title":"Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production","volume":"37","author":"Herrera-Rodriguez","year":"2019","journal-title":"Vaccine"},{"key":"B18","first-page":"304","article-title":"A simple procedure for removal of triton X-100 from protein samples","volume-title":"Analytical biochemistry","author":"Holloway","year":"1973"},{"key":"B19","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/inf.0000000000003620","article-title":"Relative effectiveness of cell-based versus egg-based quadrivalent influenza vaccines in children and adolescents in the United States during the 2019-2020 influenza season","volume":"41","author":"Imran","year":"2022","journal-title":"Pediatr. Infect. Dis. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.virol.2018.03.013","article-title":"Broadly protective anti-hemagglutinin stalk antibodies induced by live attenuated influenza vaccine expressing chimeric hemagglutinin","volume":"518","author":"Isakova-Sivak","year":"2018","journal-title":"Virology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/s0021-9673(01)93874-9","article-title":"Comparison of protein A, protein G and copolymerized hydroxyapatite for the purification of human monoclonal antibodies","volume":"476","author":"Jungbauer","year":"1989","journal-title":"J. Chromatogr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1016\/j.vaccine.2006.01.046","article-title":"Haemagglutinin quantification and identification of influenza A&B strains propagated in PER.C6 cells: A novel RP-HPLC method","volume":"24","author":"Kapteyn","year":"2006","journal-title":"Vaccine"},{"key":"B23","doi-asserted-by":"publisher","first-page":"10432","DOI":"10.1038\/s41598-018-28706-1","article-title":"The influenza virus hemagglutinin head evolves faster than the stalk domain","volume":"8","author":"Kirkpatrick","year":"2018","journal-title":"Sci. Rep."},{"key":"B24","first-page":"e0150700","article-title":"Influenza vaccine manufacturing: Effect of inactivation, splitting and site of manufacturing. Comparison of influenza vaccine production processes","volume-title":"Plos one","author":"Kon","year":"2016"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/mbio.02332-17","article-title":"NAction! How can neuraminidase-based immunity contribute to better influenza virus vaccines?","volume":"9","author":"Krammer","year":"2018","journal-title":"mBio"},{"key":"B26","doi-asserted-by":"publisher","first-page":"a028845","DOI":"10.1101\/cshperspect.a028845","article-title":"Is it possible to develop a \"universal\" influenza virus vaccine? Potential target antigens and critical aspects for a universal influenza vaccine","volume":"10","author":"Krammer","year":"2018","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1128\/jvi.03183-13","article-title":"H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge","volume":"88","author":"Krammer","year":"2014","journal-title":"J. Virology"},{"key":"B28","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.1093\/infdis\/jiy711","article-title":"Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain","volume":"219","author":"Krammer","year":"2019","journal-title":"J. Infect. Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1128\/jvi.00641-13","article-title":"Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies","volume":"87","author":"Krammer","year":"2013","journal-title":"J. Virol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1021\/acscentsci.0c00107","article-title":"The flu shot and the egg","volume":"6","author":"Krietsch Boerner","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/vaccines9010040","article-title":"Chimeric hemagglutinin-based live-attenuated vaccines confer durable protective immunity against influenza A viruses in a preclinical ferret model","volume":"9","author":"Liu","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"746447","DOI":"10.3389\/fimmu.2021.746447","article-title":"Mosaic hemagglutinin-based whole inactivated virus vaccines induce broad protection against influenza B virus challenge in mice","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"10435","DOI":"10.1128\/jvi.01715-13","article-title":"Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses","volume":"87","author":"Margine","year":"2013","journal-title":"J. Virol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"e51112","DOI":"10.3791\/51112","article-title":"Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system","author":"Margine","year":"2013","journal-title":"J. Vis. Exp. JoVE"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3389\/fimmu.2019.02005","article-title":"Vaccination with viral vectors expressing chimeric hemagglutinin, NP and M1 antigens protects ferrets against influenza virus challenge","volume":"10","author":"McMahon","year":"2019","journal-title":"Front. Immunol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to influenza virus neuraminidase: An independent correlate of protection","volume":"212","author":"Monto","year":"2015","journal-title":"J. Infect. Dis."},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1101\/2022.09.22.509041","volume-title":"Commercial influenza vaccines vary in both the structural arrangements of HA complexes and in induction of antibodies to cross-reactive HA epitopes","author":"Myers","year":"2022"},{"key":"B38","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","article-title":"A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial","volume":"27","author":"Nachbagauer","year":"2021","journal-title":"Nat. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjvaccines.2016.15","article-title":"A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice","volume":"1","author":"Nachbagauer","year":"2016","journal-title":"npj Vaccines"},{"key":"B40","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3390\/vaccines6030047","article-title":"A live-attenuated prime, inactivated boost vaccination strategy with chimeric hemagglutinin-based universal influenza virus vaccines provides protection in ferrets: A confirmatory study","volume":"6","author":"Nachbagauer","year":"2018","journal-title":"Vaccines"},{"key":"B41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41541-017-0026-4","article-title":"A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies","volume":"2","author":"Nachbagauer","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B42","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/s41591-019-0463-x","article-title":"Novel correlates of protection against pandemic H1N1 influenza A virus infection","volume":"25","author":"Ng","year":"2019","journal-title":"Nat. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"e0194830","DOI":"10.1371\/journal.pone.0194830","article-title":"An immuno-assay to quantify influenza virus hemagglutinin with correctly folded stalk domains in vaccine preparations","volume":"13","author":"Rajendran","year":"2018","journal-title":"PLOS ONE"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1016\/j.vaccine.2015.09.029","article-title":"Improved stability of recombinant hemagglutinin using a formulation containing sodium thioglycolate","volume":"33","author":"Rhodes","year":"2015","journal-title":"Vaccine"},{"key":"B45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41541-020-00227-x","article-title":"Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans","volume":"5","author":"Richards","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1128\/jvi.02598-15","article-title":"Vaccination with vesicular stomatitis virus-vectored chimeric hemagglutinins protects mice against divergent influenza virus challenge strains","volume":"90","author":"Ryder","year":"2015","journal-title":"J. Virol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e2074","DOI":"10.1002\/rmv.2074","article-title":"Inactivation methods for whole influenza vaccine production","volume":"29","author":"Sabbaghi","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"B48","first-page":"223","article-title":"A single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen. Proposals for an assay method for the haemagglutinin content of influenza vaccines","volume":"52","author":"Schild","year":"1975","journal-title":"Bull. World Health Organ"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/jvi.00333-19","article-title":"Development of influenza B universal vaccine candidates using the \"mosaic\" hemagglutinin approach","volume":"93","author":"Sun","year":"2019","journal-title":"J. Virol."},{"key":"B50","first-page":"13580","article-title":"Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin","volume-title":"Journal of virology","author":"Tan","year":"2014"},{"key":"B51","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1371\/journal.pmed.0030237","article-title":"Human monoclonal antibody combination against SARS coronavirus: Synergy and coverage of escape mutants","volume":"3","author":"ter Meulen","year":"2006","journal-title":"PLoS Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/1741-7015-11-153","article-title":"Comparing influenza vaccine efficacy against mismatched and matched strains: A systematic review and meta-analysis","volume":"11","author":"Tricco","year":"2013","journal-title":"BMC Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jaci.2009.12.015","article-title":"Ovalbumin content in 2009 to 2010 seasonal and H1N1 monovalent influenza vaccines","volume":"125","author":"Waibel","year":"2010","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2023.1097349\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T01:23:17Z","timestamp":1685928197000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2023.1097349\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":53,"alternative-id":["10.3389\/fbioe.2023.1097349"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2023.1097349","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"article-number":"1097349"}}